Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677698 | 0.80 | HTR1A (0.41) | CES1FAAHCES2PLA2G6 | |
| SCHEMBL890300 | 0.78 | MAPT (0.50) | CHRM1CHRM2CHRM4CHRM3MAPT | |
| SCHEMBL13461104 | 0.78 | CES2 (0.50) | CES1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9522178 | 0.78 | MAPT (0.38) | CES1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14535086 | 0.74 | CES1 (0.68) | CES1FAAHCES2PLA2G6MAPT | |
| SCHEMBL6129960 | 0.73 | CYP2D6 (0.40) | CES1FAAHCES2PLA2G6 | |
| SCHEMBL29193673 | 0.73 | KDM1A (0.35) | CHRM1CHRM2CHRM4CHRM3MAPT | |
| SCHEMBL11685475 | 0.73 | MEN1 (0.39) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL14950068 | 0.72 | FAAH (0.67) | CES1FAAHCES2PLA2G6MAPT | |
| SCHEMBL19928053 | 0.72 | CES1 (0.39) | CES1FAAHCES2PLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | CES1 2170/4885CHRM1 283/4885CHRM2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.